Annals of Surgery · 2020 · 82 citations · 25 references
MedicineOncologySurgeryCardiac TransplantationTransplant ImmunologyTransplant SurgeryDeceased Donor CareDeceased Donor TransplantationHepatic PerfusionLiver TransplantationTransplant OutcomesCirculatory Death DonationDeceased Donor Liver TransplantationHepatocellular Carcinoma TransplantationLiver Graft PerfusionOxygenated PerfusionRecurrenceTumor Load Assessment
OBJECTIVE: The aim of this study was to investigate tumor recurrence after liver transplantation for hepatocellular carcinoma (HCC), with and without hypothermic oxygenated liver perfusion (HOPE) before transplantation. PATIENTS AND METHODS: We analyzed all liver recipients with HCC, transplanted between January 2012 and September 2019 with donation after circulatory death (DCD) livers after previous end-ischemic HOPE-treatment (n = 70, Center A). Tumor parameters and key confounders were compared to consecutive recipients with HCC, transplanted during the same observation period with an unperfused DBD liver (n = 70). In a next step, we analyzed unperfused DCD (n = 70) and DBD liver recipients (n = 70), transplanted for HCC at an external center (Center B). RESULTS: Tumor parameters were not significantly different between HOPE-treated DCD and unperfused DBD liver recipients at Center A. One-third of patients were outside established tumor thresholds, for example, Milan criteria, in both groups. Despite no difference in tumor load, we found a 4-fold higher tumor recurrence rate in unperfused DBD livers (25.7%, 18/70), compared to only 5.7% (n = 4/70) recipients with tumor recurrence in the HOPE-treated DCD cohort (P = 0.002) in Center A. The tumor recurrence rate was also twice higher in unperfused DCD and DBD recipients at the external Center B, despite significant less cases outside Milan. HOPE-treatment of DCD livers resulted therefore in a 5-year tumor-free survival of 92% in HCC recipients, compared to 73%, 82.7%, and 81.2% in patients receiving unperfused DBD or DCD livers, from both centers. CONCLUSION: We suggest that a simple machine liver perfusion approach appears advantageous to protect from HCC recurrence after liver transplantation, despite extended tumor criteria.
25
Are There Better Guidelines for Allocation in Liver Transplantation?
Philipp Dutkowski, Christian E. Oberkofler, Ksenija Slankamenac et al. · Annals of Surgery · 2011 · 410 citations
Medicine, Surgery, Risk Assessment +16
HOPE for human liver grafts obtained from donors after cardiac death
Philipp Dutkowski, Andrea Schlegel, Michelle de Oliveira et al. · Journal of Hepatology · 2013 · 336 citations
Medicine, Cardiology, Surgery +14